PATROL Study

Research Topic: Prostate Cancer

Study Title: PATROL: Prostate Cancer Screening for People AT Genetic Risk For Aggressive Disease

Research Team:
Matthew Cooperberg, MD, MPH, Principal Investigator (PI)
Karina Acevedo, Clinical Research Coordinator

Sponsor: BRCA Research & Cure Alliance (CureBRCA) and Canary Foundation

Study Overview

This study is following people with BRCA2 and related inherited gene mutations to better understand prostate cancer risk, detection, and progression. 

Researchers will collect information about prostate-specific antigen (PSA) levels, other screening tests, biopsy results, and participants' health over time to evaluate how these measures can help identify high-grade prostate cancer and guide decisions about when a biopsy may be needed. The study will also collect information about participants' symptoms, overall health, and quality of life to better understand their experiences and improve future care for people with these inherited gene changes.

Who can join?

Green check mark
  • Age range: People with prostates ≥40 years of age.
  • Inherited mutations or suspected genes (ATM, BRCA1, BRCA2, BRIP1, CHEK2, HOXB13, MLH1, MSH2, MSH6, PALB2, PMS2, TP53, and RAD51D) associated with prostate cancer risk.
Red X
  • Current or past diagnosis of prostate cancer.
  • Medical reason that would be unsafe to have study procedures done (e.g., prostate biopsy). 
  • Received treatment meant to cure any type of cancer (except common skin cancers) within the past 12 months, such as surgery, radiation, chemotherapy, or immunotherapy.
  • Prior or current participation in a clinical trial that tests ways to prevent cancer in people with inherited (genetic) risk for prostate cancer.

What to Expect During the Study

clipboard
Research activities

Blood draws, Urine collection, Surveys, Prostate cancer screening visits.

Globe
Location

In person and remote

UCSF Mission Bay

Stick figures in a circle
How you can help
  • Participation in this study will help researchers improve prostate cancer screening for people with inherited genetic risk, including BRCA2 and related gene mutations. 
  • Participation may help researchers develop more personalized screening guidelines, improve how PSA blood test results are interpreted, identify prostate cancer earlier when it may be more treatable, and better understand quality of life and the progression of prostate cancer in genetically at-risk individuals. 
  • Knowledge gained may also help clinicians make more informed, evidence-based decisions about when a prostate biopsy is needed and improve care for future patients.

FAQ's

Up to 10 years

The study includes a first (baseline) visit and yearly visits to screen for prostate cancer. Your provider team will continue your regular yearly prostate cancer screening as part of your usual care. At these visits, we will also collect extra blood and urine samples for research. We will ask you questions about your health, medical history, quality of life, and ask you to complete surveys for up to 10 years. If you are diagnosed with prostate cancer, your care will continue based on your provider’s recommendations. If active surveillance is recommended (monitoring the cancer instead of treating it right away), your clinic visits, prostate biopsies, and other procedures will continue based on your provider’s recommendations. Study-related procedures will continue until you begin treatment to cure the cancer.

N/A

We are planning to enroll 4 people per year.

Contact us

Karina Acevedo, Clinical Research Coordinator
[email protected]
(415) 353-7615

Print this page